BACKGROUND: Treatment options for antibody-mediated rejection (AMR) are limited. Recent studies have shown that inhibition of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling can reduce inflammation and slow AMR progression. METHODS: We report our experience using monthly tocilizumab (anti-IL6R) in 25 pediatric renal transplant recipients with AMR, refractory to IVIg/Rituximab. From January 2013 to June 2019, a median (IQR) of 12 (6.019.0) doses of tocilizumab were given per patient. Serial assessments of renal function, biopsy findings, and HLA DSA (by immunodominant HLA DSA [iDSA] and relative intensity score [RIS]) were performed. RESULTS: Median (IQR) time from transplant to AMR was 41.4 (24.367.7) months, and time from AMR to first tocilizumab was 10.6 (8.317.6) months. At median (IQR) follow up of 15.8 (8.435.7) months post-tocilizumab initiation, renal function was stable except for 1 allograft loss. There was no significant decrease in iDSA or RIS. Follow up biopsies showed reduction in peritubular capillaritis (p = .015) and C4d scoring (p = .009). The most frequent adverse events were cytopenias. CONCLUSIONS: Tocilizumab in pediatric patients with refractory AMR was well tolerated and appeared to stabilize renal function. The utility of tocilizumab in the treatment of AMR in this population should be further explored.
BACKGROUND: Treatment options for antibody-mediated rejection (AMR) are limited. Recent studies have shown that inhibition of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling can reduce inflammation and slow AMR progression. METHODS: We report our experience using monthly tocilizumab (anti-IL6R) in 25 pediatric renal transplant recipients with AMR, refractory to IVIg/Rituximab. From January 2013 to June 2019, a median (IQR) of 12 (6.019.0) doses of tocilizumab were given per patient. Serial assessments of renal function, biopsy findings, and HLA DSA (by immunodominant HLA DSA [iDSA] and relative intensity score [RIS]) were performed. RESULTS: Median (IQR) time from transplant to AMR was 41.4 (24.367.7) months, and time from AMR to first tocilizumab was 10.6 (8.317.6) months. At median (IQR) follow up of 15.8 (8.435.7) months post-tocilizumab initiation, renal function was stable except for 1 allograft loss. There was no significant decrease in iDSA or RIS. Follow up biopsies showed reduction in peritubular capillaritis (p = .015) and C4d scoring (p = .009). The most frequent adverse events were cytopenias. CONCLUSIONS: Tocilizumab in pediatric patients with refractory AMR was well tolerated and appeared to stabilize renal function. The utility of tocilizumab in the treatment of AMR in this population should be further explored.
Authors: Irene K Kim; Jua Choi; Ashley Vo; Alexis Kang; Justin Steggerda; Sabrina Louie; Mark Haas; James Mirocha; J Louis Cohen; Helen Pizzo; Elaine S Kamil; Stanley C Jordan; Dechu Puliyanda Journal: Pediatr Transplant Date: 2017-09-19
Authors: Mark Haas; James Mirocha; Nancy L Reinsmoen; Ashley A Vo; Jua Choi; Joseph M Kahwaji; Alice Peng; Rafael Villicana; Stanley C Jordan Journal: Kidney Int Date: 2017-01-16 Impact factor: 10.612
Authors: M J Everly; J J Everly; L J Arend; P Brailey; B Susskind; A Govil; A Rike; P Roy-Chaudhury; G Mogilishetty; R R Alloway; A Tevar; E S Woodle Journal: Am J Transplant Date: 2009-03-16 Impact factor: 8.086
Authors: Meghan H Pearl; Anjali B Nayak; Robert B Ettenger; Dechu Puliyanda; Miguel Fernando Palma Diaz; Qiuheng Zhang; Elaine F Reed; Eileen W Tsai Journal: Pediatr Nephrol Date: 2016-04-05 Impact factor: 3.714
Authors: Farsad Eskandary; Michael Dürr; Klemens Budde; Konstantin Doberer; Roman Reindl-Schwaighofer; Johannes Waiser; Markus Wahrmann; Heinz Regele; Andreas Spittler; Nils Lachmann; Christa Firbas; Jakob Mühlbacher; Gregor Bond; Philipp F Halloran; Edward Chong; Bernd Jilma; Georg A Böhmig Journal: Trials Date: 2019-01-11 Impact factor: 2.279
Authors: M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel Journal: Am J Transplant Date: 2018-01-21 Impact factor: 8.086